Please login to the form below

Not currently logged in
Email:
Password:

Movetis launches Resolor in Germany

First market introduction of Movetis' lead medicine for chronic constipation

Following the approval of Resolor (prucalopride) in the European Economic Area in October 2009, Movetis has launched the prescription only drug in Germany. It will be used for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.

Prucalopride is the first molecule from the Movetis portfolio that has been developed into a marketed medicinal product. Movetis is a spinoff of Johnson & Johnson, established in Belgium in 2006, to develop innovative drugs for the treatment of diseases in the gastrointestinal (GI) area.

Resolor is a once-a-day oral product, available in 1mg and 2mg tablets and meets the criteria for reimbursement in Germany. 

Dirk Reyn, chief executive officer of Movetis, said: "The launch of Resolor in Germany is yet another important milestone in the relatively short history of Movetis. The market introduction in Germany was scheduled for the first quarter of 2010, and we have clearly achieved this objective. Every day we receive more and more questions from physicians, illustrating there is a clear interest for a product such as Resolor."

Movetis plans to launch Resolor in the UK in the second quarter of 2010.

The company has a broad portfolio of GI products in development for conditions including ascites, paediatric reflux, refractory gastroesophageal reflux disease and severe forms of irritable bowel syndrome.

27th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics